Phaseline

Companies › Amydis

Amydis: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 2 Phase 2; Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
AMDX-2011P
diagnostic imaging agent for cerebral amyloid angiopathy
–Phase 2Cerebral Amyloid Angiopathy; Alzheimer DiseaseDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05709314AMDX-2011PPhase 2Cerebral Amyloid AngiopathyNeurologyDec 2026
NCT06514001AMDX-2011PPhase 2Alzheimer DiseaseNeurologyJul 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Dasher Neuroscience ThromBio Appello Pharmaceuticals PhenoNet Glycomine

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.